PMS-PIRFENIDONE 267 & 801 mg: Data integrity concerns with products bioequivalence data that could lead to incorrect dosing.

Product quality

Date

2024-06-07

Country

Canada

Product

PMS-PIRFENIDONE 267 & 801 mg

Classification

Type I

Category

Drugs & medical

Source

Health Canada

Copied automatically from the Government of Canada. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer

What to do

1. Check the product name, strength and lot number against the official notice.
2. Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
3. Ask the pharmacy or supplier about a replacement or refund.

General guidance from Recall Atlas. The official notice from the Government of Canada has the exact models, batch codes and remedy, and it takes priority.

Other drugs & medical recalls in Canada

1. 2024-06-12
2. CA
   Drugs & medicalType II

   Zyn Nicotine Pouches 1.5 & 3mg: No market authorization

   Product safety

   Health CanadaOfficial notice →
3. 2024-06-10
4. CA
   Drugs & medicalType I

   BLUSelect®, BLUgriggs® and BLUperc® Products

   Performance

   Health CanadaOfficial notice →
5. CA
   Drugs & medicalType II

   Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA

   Product safety

   Health CanadaOfficial notice →
6. 2024-06-07
7. CA
   Drugs & medicalType II

   DELFIA / AutoDELFIA PIGF 1-2-3

   Performance

   Health CanadaOfficial notice →
8. CA
   Drugs & medicalType II

   Beckman Coulter Au Immunochemistry System- Immunoglobulin M (IgM)

   Performance

   Health CanadaOfficial notice →
9. CA
   Drugs & medicalType II

   NGENUITY 3D Visualization System

   Performance

   Health CanadaOfficial notice →